Summary
Valneva SE (Valneva) is a biotechnology company that develops, manufactures and commercializes vaccines for the treatment of people with infectious diseases. The company’s products include IXIARO, an encephalitis vaccine and DUKORAL, which is indicated for the prevention of cholera. It vaccines in development include candidates against clostridium difficile and lyme borreliosis. Valneva’s pre-clinical programs include vaccines against zika, chikungunya, yellow-fever and human metapneumovirus diseases. The company’s technologies include EB66 cell line, a proprietary embryonic stem cell-based technology which is used for the production of human and veterinary viral and therapeutic vaccines; and IC31, a synthetic vaccine adjuvant. Valneva has its facilities in Livingston, Solna and others. It has a presence in France, Austria, the UK, Sweden, the US, and Canada. Valneva is headquartered in Lyon, France.
Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Valneva SE, Medical Devices Deals, 2010 to YTD 2016 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Valneva SE, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 16
Private Equity 17
MVM Life Science to Invest USD16.2 Million in Valneva 17
Partnerships 19
Seqirus Enters into Distribution Agreement with Valneva 19
Valneva Enters into R&D Agreement with GlaxoSmithKline 20
Valneva Enters into Distribution Agreement with PaxVax 21
PaxVax Enters into Distribution Agreement with Valneva 22
Valneva Forms Joint Venture with BliNK Therapeutics 23
Licensing Agreements 24
Valneva Enters into Licensing Agreement with Jianshun Biosciences 24
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 25
Valneva to Enter into Licensing Agreement with Pharma Company 26
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 27
GeoVax Labs Enters into Licensing Agreement with Valneva 28
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 29
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 30
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 31
Equity Offering 32
Valneva Raises USD54 Million in Rights Offering 32
Valneva Completes Rights Offering Of Shares For US$53.5 Million 34
Asset Transactions 36
Valneva To Sell Clinical Manufacturing Operations Facility To Biological E 36
Acquisition 37
Valneva Acquires Crucell Sweden for USD54 Million 37
Valneva SE - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Valneva SE, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Valneva SE, Deals By Therapy Area, 2010 to YTD 2016 9
Valneva SE, Medical Devices Deals, 2010 to YTD 2016 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 16
MVM Life Science to Invest USD16.2 Million in Valneva 17
Seqirus Enters into Distribution Agreement with Valneva 19
Valneva Enters into R&D Agreement with GlaxoSmithKline 20
Valneva Enters into Distribution Agreement with PaxVax 21
PaxVax Enters into Distribution Agreement with Valneva 22
Valneva Forms Joint Venture with BliNK Therapeutics 23
Valneva Enters into Licensing Agreement with Jianshun Biosciences 24
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 25
Valneva to Enter into Licensing Agreement with Pharma Company 26
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 27
GeoVax Labs Enters into Licensing Agreement with Valneva 28
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 29
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 30
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 31
Valneva Raises USD54 Million in Rights Offering 32
Valneva Completes Rights Offering Of Shares For US$53.5 Million 34
Valneva To Sell Clinical Manufacturing Operations Facility To Biological E 36
Valneva Acquires Crucell Sweden for USD54 Million 37
Valneva SE, Key Competitors 38
Valneva SE, Key Employees 39
Valneva SE, Other Locations 40
Valneva SE, Subsidiaries 40
List of Figures
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Valneva SE, Medical Devices Deals, 2010 to YTD 2016 10
